1. New Zealand Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Pacific Edge Limited

Pacific Edge Limited

PEB.AX
Pacific Edge LimitedAU flagAustralian Securities Exchange
0.23
AUD
+0.00
- -
285.63MMarket Cap
Pacific Edge Limited
PEB.AX
(Australian Securities Exchange)

Recent

price

0.23

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
FRC
- -
- -
- -
- -
0.01
0.01
0.02
0.01
0.01
0.01
0.01
0.01
0.02
0.03
0.03
0.01
Revenue per Share
-0.02
-0.02
-0.02
-0.03
-0.03
-0.04
-0.05
-0.04
-0.03
-0.03
-0.02
-0.03
-0.03
-0.04
-0.04
-0.04
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.07
0.03
0.06
0.03
0.07
0.04
0.03
0.02
0.02
0.03
0.14
0.1
0.06
0.02
- -
Book Value per Share
0.01
0.07
0.03
0.07
0.03
0.08
0.05
0.03
0.03
0.02
0.03
0.14
0.1
0.07
0.03
0.01
Tangible Book Value per Share
208
262
320
337
345
387
410
466
514
581
714
768
810
811
812
945
Basic Weighted Avg Shares
- -
- -
- -
- -
2
5
8
3
4
4
8
11
20
24
22
11
Sales/Revenue/Turnover
-584,798.4
-48,059.53
-48,743.9
-6,937.73
-682.28
-359.64
-278.5
-630.74
-506.65
-453.91
-219.74
-193.85
-170.58
-153.85
-156.11
-339.71
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
- -
1
- -
- -
1
3
2
2
Depreciation Expense
-3
-4
-7
-10
-11
-16
-21
-20
-18
-19
-14
-20
-27
-30
-30
-36
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-624,600
-42,412.9
-46,045.8
-6,853.54
-564.78
-315.07
-260.24
-577.76
-469.43
-432.17
-184.69
-172.9
-137.46
-123.54
-137.03
-311.14
Profit Margin (%)
4
17
10
20
10
29
20
26
21
26
42
106
78
50
21
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
1
- -
3
1
- -
LT Debt
3
18
11
22
12
30
21
17
14
15
25
108
83
55
26
11
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-162.53
-39.99
-47.94
-61.4
-67.59
-84.75
-96.3
-136.45
-177.13
-213.32
-96.67
-31.78
-29.67
-47.05
-90.32
-348.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.34%
32.52%
-59.14%
Free Cash Flow
29.45%
41.31%
-89.63%
Net Income, GAAP
10.52%
21.16%
19.51%
Sales/Revenue/Turnover
19.31%
17.18%
-47.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
24
2025
- -
- -
- -
- -
22
2026
- -
- -
- -
- -
11

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
- -
- -
-0.04
2026
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Avricore Health Inc. (AVCR.V)
Imagion Biosystems Limited (IBXXF)
Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
PAREXEL Intl Corp. (PRXL)
StageZero Life Sciences Ltd. (SZLSF)
Stratec SE (SBS.DE)
Business
Pacific Edge Limited (NZX, ASX: PEB) is a global cancer diagnostics company that develops and commercializes bladder cancer diagnostic and prognostic tests, including its flagship Cxbladder suite of products comprising Cxbladder Triage for frontline risk stratification of hematuria patients, Cxbladder Detect for enhanced detection in low-probability cases, Cxbladder Monitor for non-invasive surveillance of recurrent disease, and emerging Triage Plus and Monitor Plus tests; the company operates CLIA-certified laboratories in New Zealand and the United States to process tests worldwide, with additional research into diagnostics for gastric, colorectal, endometrial cancers and melanoma. Founded in 2001 and headquartered at the Centre for Innovation, 87 St David Street in Dunedin, New Zealand, Pacific Edge serves urologists, healthcare providers and patients primarily in North America, Europe and Australasia through its commercial segment focused on sales, marketing and laboratory operations, complemented by a research and development segment advancing molecular oncology and bioinformatics capabilities. In 2025, the company executed a NZ$20.7 million capital raise via a NZ$15 million institutional placement and NZ$5.7 million share purchase plan to fund US Medicare coverage efforts including reconsideration requests for Triage and Triage Plus, clinical evidence generation for its next-generation portfolio, and product innovation toward in vitro diagnostic kits for decentralized international markets; additionally, the US Centers for Medicare & Medicaid Services recommended a final gapfill price of US$1,328 for Cxbladder Triage Plus, surpassing the prior draft proposal.